NIH-3T3 cells expressing high levels of the c-ras proto-oncogene display reduced platelet derived growth factor-stimulated phospholipase activity.
NIH-3T3 cells expressing elevated levels of the normal human c-Ha-ras proto-oncogene (c-ras) exhibit reduced platelet derived growth factor-stimulated phospholipase activity. Three clonal cell lines of NIH-3T3 cells expressing different levels of c-ras have been isolated and characterized. The level of c-ras expression correlates inversely with PDGF-stimulated phospholipase activity as monitored by prostaglandin E2 (PGE2) production. In addition, high levels of c-ras expression produce cells with morphological and biochemical characteristics indistinguishable from NIH-3T3 cells transformed by EJ-ras. These data suggest that abnormal c-ras expression can attenuate growth factor-stimulated phospholipase activity in NIH-3T3 cells, in a manner analogous to that observed in cells transformed by EJ-ras.
Cell Biology, Upjohn Company, Kalamazoo, Michigan 49001.
P L
PL
Olinger
R R
RR
Gorman
D000818:Animals; D002460:Cell Line; D002471:Cell Transformation, Neoplastic; D015232:Dinoprostone; D005347:Fibroblasts / Q000166:cytology / Q000378:metabolism*; D005786:Gene Expression Regulation; D006801:Humans; D051379:Mice; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D011458:Prostaglandins E / Q000096:biosynthesis; D000090063:Proto-Oncogene Mas; D011519:Proto-Oncogenes; D014162:Transfection; D010738:Type C Phospholipases / Q000378:metabolism*
C000715470:MAS1 protein, human; D010982:Platelet-Derived Growth Factor; D011458:Prostaglandins E; D000090063:Proto-Oncogene Mas; D010738:Type C Phospholipases; D015232:Dinoprostone